WEBSITE BSE:535217 NSE: HPC BIO Inc. Year: 2002 Industry: Agriculture My Bucket: Add Stock
Last updated: 00:00
No Notes Added Yet
1. Business Overview
HPC Biosciences Ltd. operates in the agriculture sector in India, primarily focusing on biological solutions. Given its name, the company is likely involved in the research, development, production, and marketing of agricultural inputs based on biological processes. This could include bio-fertilizers, bio-pesticides, bio-stimulants, plant growth regulators, soil health products, and potentially specialized seeds or animal nutrition products derived from biotechnology. Its core business model is to provide farmers with sustainable and often eco-friendly alternatives or complements to traditional chemical inputs, aiming to improve crop yield, soil health, and overall agricultural productivity. The company primarily makes money through the sale of these agricultural biological products directly to farmers, through a network of distributors, or via institutional sales to larger agricultural enterprises.
2. Key Segments / Revenue Mix
Specific revenue mix and key segments are not available in the provided information. However, based on the company name and industry, potential segments might include:
Bio-Crop Care Products: Bio-fertilizers, bio-pesticides, bio-fungicides, and bio-herbicides.
Plant Nutrition & Soil Health: Bio-stimulants, micronutrients, and soil conditioners.
Seed Treatment & Technologies: Biological seed treatment solutions for enhanced germination and early plant vigor.
Research & Development Services: If it develops proprietary technologies, it might also license them or offer related services.
Without specific data, it is not possible to quantify the contribution of each potential segment.
3. Industry & Positioning
The Indian agriculture industry is vast and diverse, characterized by a large number of small and marginal farmers, dependency on monsoons, and significant government intervention. The market for agricultural biologicals is an emerging but growing segment, driven by increasing awareness of environmental sustainability, soil degradation, residue concerns from chemical pesticides, and government promotion of organic farming. HPC Biosciences likely positions itself as a provider of advanced, eco-friendly, and sustainable solutions for modern agriculture. Its "biosciences" focus suggests a technology-driven approach, potentially competing with both traditional chemical input providers and other specialized biological product companies, aiming for differentiation through R&D and product efficacy.
4. Competitive Advantage (Moat)
The company's competitive advantages, if any, could stem from:
Proprietary R&D and Formulations: Developing unique, effective biological strains or formulations that offer superior performance. This could include patents or trade secrets.
Regulatory Approvals & Licenses: Successfully navigating the complex regulatory landscape for biological products, which can be a significant barrier to entry.
Brand Reputation & Farmer Trust: Building trust among farmers through consistent product quality and demonstrated efficacy, leading to repeat purchases.
Distribution Network: Establishing a robust and wide-reaching distribution network across diverse agricultural regions in India is crucial for reaching farmers effectively.
Cost Efficiency in Production: Ability to produce biological inputs at a competitive cost without compromising quality.
The strength and presence of these potential moats for HPC Biosciences Ltd. are not explicitly known.
5. Growth Drivers
Growing Demand for Sustainable Agriculture: Increasing farmer and consumer awareness of environmental impact, soil health, and demand for residue-free produce.
Government Support & Policies: Initiatives like organic farming promotion, subsidies for bio-inputs, and climate-resilient agriculture programs.
Technological Advancements: Continuous innovation in biotechnology leading to more effective and targeted biological solutions.
Yield Improvement Focus: Farmers constantly seek ways to improve crop yields and quality, which advanced biological products can contribute to.
Export Potential: Growing global demand for organic and sustainably grown agricultural products could open export markets.
6. Risks
Monsoon Dependency: The Indian agriculture sector is heavily reliant on monsoon rains, which can impact farmer purchasing power and crop cycles.
Price Volatility of Agricultural Commodities: Fluctuations in crop prices can affect farmer income and their ability to invest in advanced inputs.
Intense Competition: Competition from both established chemical fertilizer/pesticide players (who are also entering the biologicals space) and other biological solution providers.
Regulatory Hurdles: Stringent and evolving regulatory processes for new biological products can be time-consuming and costly.
Farmer Acceptance & Education: Overcoming traditional farming practices and educating farmers about the benefits and proper application of biological products.
R&D Failure: Investments in R&D may not always translate into commercially viable products.
Counterfeit Products: Risk of spurious or counterfeit products impacting brand reputation and sales.
7. Management & Ownership
Specific details regarding the promoters, management quality, or precise ownership structure for HPC Biosciences Ltd. are not provided. In India, many listed companies have a significant portion of ownership held by founding families or promoter groups, alongside institutional investors and the public. The quality of management is critical for navigating the complexities of the agricultural sector, including R&D, manufacturing, distribution, and regulatory compliance.
8. Outlook
HPC Biosciences Ltd. operates in a promising niche within the Indian agriculture sector, benefiting from the global shift towards sustainable farming and increasing demand for biological inputs. The "biosciences" focus positions it in a high-growth segment, potentially offering superior products with environmental benefits. However, success hinges on its ability to continually innovate, secure regulatory approvals, effectively reach and educate a vast and diverse farmer base, and withstand competition from both local and international players. The company's outlook is tied to its R&D capabilities, strength of its distribution network, and its ability to build farmer trust through consistent product performance. While opportunities for growth are significant, the inherent risks associated with agriculture (weather, policy, commodity prices) and the challenges of commercializing new technologies require careful execution and strong operational management.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹410 Cr.
Stock P/E 350.4
P/B 12.5
Current Price ₹25.7
Book Value ₹ 2.1
Face Value 1
52W High ₹0
Dividend Yield 0%
52W Low ₹ 0
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2013 | Sep 2016 | Sep 2017 |
|---|---|---|---|
| Net Sales | 1 | 1 | 1 |
| Other Income | 0 | 0 | 0 |
| Total Income | 1 | 1 | 1 |
| Total Expenditure | -0 | 0 | 0 |
| Operating Profit | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 |
| Depreciation | 1 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 |
| Adjustments | -0 | -0 | -0 |
| Profit After Adjustments | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0 | 0 | 0 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 3 | 5 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 3 | 5 | 4 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Total Expenditure | 0 | -0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Operating Profit | -0 | 3 | 4 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | 3 | 3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0 | 3 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 3 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Adjusted Earnings Per Share | -0 | 0.9 | 0.2 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 100% | 0% | 0% | 0% |
| Operating Profit CAGR | 100% | 26% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 0% | -1% | -0% | -5% |
| ROE Average | 4% | 2% | 2% | 15% |
| ROCE Average | 4% | 2% | 2% | 15% |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 0 | 5 | 28 | 29 | 30 | 30 | 31 | 31 | 31 | 32 | 33 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Total Liabilities | 0 | 5 | 28 | 29 | 30 | 30 | 31 | 31 | 32 | 32 | 33 |
| Fixed Assets | 0 | 1 | 11 | 10 | 8 | 7 | 6 | 5 | 4 | 4 | 3 |
| Other Non-Current Assets | 0 | 0 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Total Current Assets | 0 | 4 | 11 | 13 | 17 | 19 | 21 | 22 | 24 | 25 | 26 |
| Total Assets | 0 | 5 | 28 | 29 | 30 | 30 | 31 | 31 | 32 | 32 | 33 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -0 | -0 | 3 | 4 | 0 | -0 | 1 | 0 | 1 | 1 | 1 |
| Cash Flow from Investing Activities | 0 | -1 | -23 | -5 | 1 | 0 | -2 | -0 | -1 | -1 | 0 |
| Cash Flow from Financing Activities | 0 | 2 | 20 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Inflow / Outflow | -0 | 0 | 1 | -0 | 0 | -0 | -1 | -0 | 0 | 0 | 1 |
| Closing Cash & Cash Equivalent | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| # | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.01 | 0.87 | 0.19 | 0.08 | 0.04 | 0.03 | 0.03 | 0.01 | 0.03 | 0.02 | 0.07 |
| CEPS(Rs) | -0.01 | 0.91 | 0.27 | 0.16 | 0.13 | 0.12 | 0.09 | 0.07 | 0.08 | 0.06 | 0.11 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.49 | 1.37 | 1.72 | 1.79 | 1.84 | 1.87 | 1.91 | 1.93 | 1.96 | 1.99 | 2.06 |
| Core EBITDA Margin(%) | 0 | 109.61 | 90.31 | 73.68 | 64.61 | 93.83 | 60.86 | 48.54 | 75.32 | 72.26 | 70.83 |
| EBIT Margin(%) | 0 | 105.16 | 62.57 | 36.29 | 24.46 | 27.44 | 25.2 | 12.33 | 36.17 | 29.94 | 52.14 |
| Pre Tax Margin(%) | 0 | 105.16 | 62.57 | 36.28 | 24.45 | 27 | 25.03 | 11.9 | 36.07 | 29.92 | 52.12 |
| PAT Margin (%) | 0 | 105.16 | 62.52 | 35.7 | 22.78 | 24.65 | 22.48 | 10.12 | 34.63 | 28.06 | 51.16 |
| Cash Profit Margin (%) | 0 | 109.61 | 90.41 | 74.96 | 68.41 | 98.64 | 66.39 | 53.41 | 79.37 | 78.87 | 73.59 |
| ROA(%) | -0.6 | 124.92 | 18.25 | 4.32 | 2.39 | 1.54 | 1.66 | 0.63 | 1.75 | 1.05 | 3.58 |
| ROE(%) | -1.02 | 125.8 | 18.47 | 4.41 | 2.44 | 1.56 | 1.68 | 0.64 | 1.78 | 1.07 | 3.62 |
| ROCE(%) | -0.61 | 124.95 | 18.43 | 4.45 | 2.6 | 1.73 | 1.88 | 0.78 | 1.86 | 1.14 | 3.69 |
| Receivable days | 0 | 43.8 | 55.17 | 0 | 233.6 | 512.37 | 577.12 | 848.13 | 1192.36 | 1630.41 | 888.1 |
| Inventory Days | 0 | 97.88 | 69.61 | 98.08 | 87.85 | 188.39 | 200.57 | 201.1 | 205.59 | 256.43 | 107.96 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 22 | 679.59 | 1040.72 | 1446.37 | 1526.73 | 3296.75 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 2.39 | 29.38 | 25.06 | 22.33 | 25.4 | 21.03 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0 | 0.57 | 13.63 | 242.49 | 236.97 | 356.75 | 343.1 | 332.72 | 9.81 | 13.06 | 6.85 |
| EV/Core EBITDA(x) | -147.6 | 0.52 | 15.07 | 321.01 | 338.13 | 351.75 | 496.53 | 598.21 | 12.12 | 16.17 | 9.19 |
| Net Sales Growth(%) | 0 | 0 | 64.32 | -27.31 | -10.61 | -39.64 | 20.91 | -13.87 | -17.73 | -25.03 | 90.55 |
| EBIT Growth(%) | -150 | 0 | -2.23 | -57.85 | -39.74 | -32.3 | 11.04 | -57.85 | 141.33 | -37.95 | 231.87 |
| PAT Growth(%) | -150 | 0 | -2.31 | -58.49 | -42.95 | -34.69 | 10.27 | -61.22 | 181.45 | -39.26 | 247.42 |
| EPS Growth(%) | -150 | 0 | -78.58 | -58.51 | -42.89 | -34.62 | 10.03 | -61.32 | 182.31 | -39.23 | 247.39 |
| Debt/Equity(x) | 0.68 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 98.4 | 7394.4 | 76.31 | 27.43 | 219.48 | 192.77 | 52.59 | 47.41 | 42.49 | 53.95 | 92.99 |
| Quick Ratio(x) | 98.4 | 5840 | 69 | 25.7 | 210.98 | 180.16 | 49.55 | 45.46 | 40.91 | 52.19 | 91.04 |
| Interest Cover(x) | 0 | 0 | 7949.78 | 3936.3 | 3272.56 | 63.08 | 150.94 | 28.83 | 369.11 | 1956.75 | 2897.08 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.